WO2026138939 - ANTI-SIGLEC-8 ANTIBODY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/138939
Publication Date
02.07.2026
International Application No.
PCT/CN2025/145484
International Filing Date
25.12.2025
Title **
[English]
ANTI-SIGLEC-8 ANTIBODY AND USE THEREOF
[French]
ANTICORPS ANTI-SIGLEC-8 ET SON UTILISATION
[Chinese]
抗SIGLEC-8抗体及其应用
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
LIU, Xianqin
CHEN, Lingjia
ZHONG, Yuting
OU, Jinxin
LIANG, Jinchan
CHEN, Junyou
LI, Jiaping
WANG, Zhiwei
YAN, Qiuxian
HUANG, Xianming
LI, Shengfeng
Priority Data
202411934809.1
25.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1997 | |
| EPO | Filing, Examination, Granting | 15487 | |
| Japan | Filing, Examination, Granting | 2441 | |
| South Korea | Filing, Examination, Granting | 2684 | |
| USA | Filing, Examination, Granting | 6940 |
Total:
29,549
Contact Us
Abstract[English]
Provided are an anti-Siglec-8 antibody or antigen-binding fragment, the use thereof in the preparation of a drug for treating a condition mediated by eosinophils and/or mast cells, and a composition and kit containing the anti-Siglec-8 antibody or antigen-binding fragment.[French]
L'invention concerne un anticorps anti-Siglec-8 ou un fragment de liaison à l'antigène, son utilisation dans la préparation d'un médicament pour le traitement d'un état médié par des éosinophiles et/ou des mastocytes, et une composition et un kit contenant l'anticorps anti-Siglec-8 ou le fragment de liaison à l'antigène.[Chinese]
提供了抗Siglec-8抗体或抗原结合片段，及其在制备用于治疗嗜曙红细胞和/或肥大细胞介导的病症中的用途，以及包含该抗Siglec-8抗体或抗原结合片段的组合物和试剂盒。